Literature DB >> 8390325

Congenital endplate acetylcholinesterase deficiency.

D O Hutchinson1, T J Walls, S Nakano, S Camp, P Taylor, C M Harper, R V Groover, H A Peterson, D G Jamieson, A G Engel.   

Abstract

Endplate acetylcholinesterase (AChE) consists of globular catalytic subunits attached to the basal lamina by a collagen-like tail. Different genes encode the catalytic subunit and the tail portion of the enzyme. Endplate AChE deficiency was reported previously in a single case (Engel et al., 1977, patient 1). We describe here our observations in four additional patients (patients 2-5). Three cases were sporadic; patients 2 and 3 were sisters. All had generalized weakness increased by exertion but ophthalmoparesis was not a constant feature. All had mild slowing of the pupillary light reflex; other dysautonomic features were absent. None benefited from anticholinesterase therapy. All patients had a decremental electromyogram response; in four of the five patients, single nerve stimuli evoked a repetitive response. Miniature endplate potential amplitude was reduced in patient 5 only. Endplate amplitudes and currents were prolonged but the open-time of the acetylcholine receptor ion channel was normal. In patients 1-4 the quantal content of the endplate potential was reduced due to a reduced number of readily releasable quanta. Quantitative electron microscopy revealed abnormally small nerve terminals, abnormal encasement of the presynaptic membrane by Schwann cells and degeneration of junctional folds and of organelles in the junctional sarcoplasm. Acetylcholinesterase was absent from all endplates of all patients by cytochemical and immunocytochemical criteria. Density gradient ultracentrifugation of muscle extracts from patients 1, 3, 4 and 5 revealed an absence of the collagen-tailed form of the enzyme in patients 1, 3 and 4 but not in patient 5. The kinetic properties of the residual AChE in muscle were normal. Erythrocyte AChE activity and Km values, determined in three patients, were also normal. Studies of the catalytic subunit gene of AChE in patients 2 and 3 revealed no abnormality in those exons that encode the domain to which the tail subunit binds. In patients 1-4 the molecular defect is likely to reside in the gene encoding the tail subunit of AChE, or in a protein necessary to assemble the catalytic and tail subunits. In patient 5, the absence of AChE from the endplate may be due to a faulty tail subunit, a defect in the basal lamina site that binds the tail subunit or failure of transport of the assembled asymmetric enzyme from the cell interior to the basal lamina. The cause of the weakness in these patients is not fully understood but possible mechanisms are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390325     DOI: 10.1093/brain/116.3.633

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  25 in total

1.  Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia.

Authors:  Teerin Liewluck; Duygu Selcen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-09-23       Impact factor: 3.217

Review 2.  Muscle channelopathies and critical points in functional and genetic studies.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

3.  Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.

Authors:  Grace M McMacken; Sally Spendiff; Roger G Whittaker; Emily O'Connor; Rachel M Howarth; Veronika Boczonadi; Rita Horvath; Clarke R Slater; Hanns Lochmüller
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

4.  hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome.

Authors:  Akio Masuda; Xin-Ming Shen; Mikako Ito; Tohru Matsuura; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2008-09-20       Impact factor: 6.150

5.  Technical report: exploring the basis of congenital myasthenic syndromes in an undergraduate course, using the model organism, Caenorhabditis elegans.

Authors:  Bonnie Kaas; Avinash R Vaidya; Amanda Leatherman; Stephanie Schleidt; Rebecca Eustance Kohn
Journal:  Invert Neurosci       Date:  2010-04-30

Review 6.  Current status of the congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-11-21       Impact factor: 4.296

7.  Congenital end-plate acetylcholinesterase deficiency caused by a nonsense mutation and an A-->G splice-donor-site mutation at position +3 of the collagenlike-tail-subunit gene (COLQ): how does G at position +3 result in aberrant splicing?

Authors:  K Ohno; J M Brengman; K J Felice; D R Cornblath; A G Engel
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

8.  Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.

Authors:  Hacer Durmus; Xin-Ming Shen; Piraye Serdaroglu-Oflazer; Bulent Kara; Yesim Parman-Gulsen; Coskun Ozdemir; Joan Brengman; Feza Deymeer; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2017-11-28       Impact factor: 4.296

9.  Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme.

Authors:  K Ohno; J Brengman; A Tsujino; A G Engel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

10.  Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients.

Authors:  Duygu Selcen; Margherita Milone; Xin-Ming Shen; C Michel Harper; Anthony A Stans; Eric D Wieben; Andrew G Engel
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.